Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Urea Cycle01:23

Urea Cycle

The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
Hepatic Encephalopathy01:29

Hepatic Encephalopathy

DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic shunting—including...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
Disorders of the Nervous Tissue01:28

Disorders of the Nervous Tissue

Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Design of an adaptive randomized clinical trial of intravenous citrulline for sickle cell pain crisis in the emergency department.

Contemporary clinical trials communications·2023
Same author

Development of a robust 30-minute reverse-phase high pressure liquid chromatography method to measure amino acids using widely available equipment and its comparison to current clinical ion-exchange chromatography measurement.

Molecular genetics and metabolism reports·2022
Same author

Late Onset Ornithine Transcarbamylase Deficiency Triggered by an Acute Increase in Protein Intake: A Review of 10 Cases Reported in the Literature.

Case reports in genetics·2020
Same author

Enzyme studies in combined carboxylase deficiency.

Annals of the New York Academy of Sciences·2015
Same author

MRI characteristics of globus pallidus infarcts in isolated methylmalonic acidemia.

AJNR. American journal of neuroradiology·2014
Same author

High Intellectual Function in Individuals with Mutation-Positive Microform Holoprosencephaly.

Molecular syndromology·2012

Related Experiment Video

Updated: Jul 9, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Neurological implications of urea cycle disorders.

A L Gropman1, M Summar, J V Leonard

  • 1Department of Neurology, Children's National Medical Center and the George Washington University of the Health Sciences, 111 Michigan Avenue, N. W., Washington, DC 20010, USA. agropman@cnmc.org

Journal of Inherited Metabolic Disease
|November 27, 2007
PubMed
Summary

Urea cycle disorders cause hyperammonaemia, leading to brain dysfunction. New neuroprotective strategies targeting brain signaling pathways show promise for treating these rare genetic conditions.

Related Experiment Videos

Last Updated: Jul 9, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Area of Science:

  • Biochemistry
  • Neuroscience
  • Genetics

Background:

  • Urea cycle disorders (UCDs) are rare genetic conditions impairing ammonia detoxification.
  • Hyperammonaemia, a consequence of UCDs, causes severe central nervous system dysfunction.
  • Both acute and chronic hyperammonaemia induce significant alterations in neurotransmitter systems.

Purpose of the Study:

  • To review the neurological consequences of hyperammonaemia in UCDs.
  • To explore current and emerging therapeutic strategies for UCDs.
  • To highlight the potential of neuroprotective interventions.

Main Methods:

  • Review of existing literature on UCDs, hyperammonaemia, and neurological effects.
  • Analysis of neuropathological findings and neuroimaging markers (e.g., 1H MRS).
  • Evaluation of therapeutic approaches, including ammonia-lowering agents and neuroprotection.

Main Results:

  • Acute hyperammonaemia causes excitotoxicity via NMDA receptor activation and astrocyte dysfunction.
  • Chronic hyperammonaemia leads to adaptive changes in NMDA receptors and the glutamate-nitric oxide-cGMP pathway, affecting cognition.
  • Neuroimaging can detect metabolic alterations like elevated glutamine and reduced myoinositol.

Conclusions:

  • Hyperammonaemia profoundly impacts brain function through distinct mechanisms in acute and chronic settings.
  • While ammonia-lowering agents are standard, neuroprotective strategies offer new therapeutic avenues.
  • Targeting pathways like cGMP with phosphodiesterase inhibitors may restore cognitive functions in UCDs.